Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LIGNOSPAN FORTE vs MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Lidocaine and prilocaine stabilize neuronal membranes by inhibiting sodium ion influx, thereby blocking initiation and conduction of nerve impulses.
Local anesthetic that blocks voltage-gated sodium channels in neuronal membranes, preventing propagation of action potentials and transmission of pain signals.
Local anesthesia for dental procedures,Local anesthesia for minor surgical procedures
Local and regional infiltration anesthesia,Peripheral nerve blocks,Dental anesthesia
Adults: 2% lidocaine with 1:100,000 epinephrine, max 7 mg/kg lidocaine (500 mg) without epinephrine or 4.5 mg/kg (300 mg) with epinephrine; for dental infiltration or nerve block, 1-2 m L per site.
Dental infiltration or nerve block: 1-2 cartridges (36-72 mg mepivacaine; 0.009-0.018 mg levonordefrin) of 2% solution with 1:20,000 levonordefrin; maximum dose: 4.4 mg/kg mepivacaine (not to exceed 300 mg) per appointment.
Terminal elimination half-life of lidocaine: 1.5–2 hours; in hepatic impairment or heart failure, may extend to >4 hours. For the vasoconstrictor (epinephrine), half-life is approximately 2 minutes due to rapid uptake and metabolism.
Terminal elimination half-life is approximately 2-3 hours in adults. In neonates, half-life is prolonged (8-10 hours due to immature hepatic function). Clinical context: Short half-life reduces risk of systemic accumulation with repeated doses.
Lidocaine: Hepatic metabolism via CYP1A2 and CYP3A4 to active metabolites; prilocaine: Hepatic metabolism to o-toluidine and other metabolites.
Primarily hepatic via N-demethylation by CYP1A2; minor metabolism by CYP3A4. Metabolites excreted renally.
Renal excretion of metabolites (predominantly 4-hydroxy-2,6-xylidine and other conjugates): ~90%; biliary/fecal: <10% as unchanged drug.
Mepivacaine is primarily metabolized in the liver via N-demethylation and hydroxylation. Less than 5% is excreted unchanged in urine. Hepatic clearance accounts for >90% of elimination; renal excretion of metabolites accounts for the remainder. Fecal elimination is minimal (<2%).
Lidocaine: ~65–75% bound to alpha-1-acid glycoprotein and albumin; epinephrine: ~50–60% bound to plasma proteins (mainly albumin).
Approximately 75-85% bound to alpha-1-acid glycoprotein (orosomucoid) and less extensively to albumin. Binding is concentration-dependent.
Lidocaine: Vd ~1.1–1.7 L/kg, indicating extensive tissue distribution; epinephrine: Vd ~0.5–1.0 L/kg (large for a catecholamine).
Volume of distribution (Vd) is approximately 0.8-1.0 L/kg, indicating extensive tissue distribution. Higher Vd in infants (2-3 L/kg) due to larger extracellular fluid compartment.
Oral: <30% (extensive first-pass metabolism); intramuscular: ~100% (rapid absorption); subcutaneous infiltration: 100% (local effect); intravenous: 100%.
Mepivacaine is not administered orally due to extensive first-pass metabolism. For local infiltration or regional administration, bioavailability is essentially 100% at the site of administration. Intravenous bioavailability is 100% by definition.
No specific adjustment required; lidocaine is hepatically metabolized; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of metabolites.
GFR ≥ 50 m L/min: no adjustment. GFR 30-49 m L/min: consider reducing dose by 25% due to potential accumulation of metabolites. GFR < 30 m L/min: avoid or use with caution; reduce dose by 50% and monitor for CNS toxicity.
Avoid in severe hepatic impairment (Child-Pugh class C); for moderate impairment (Child-Pugh B), reduce dose by 50% and monitor for toxicity.
Child-Pugh A: no adjustment. Child-Pugh B: consider 50% dose reduction. Child-Pugh C: contraindicated due to impaired metabolism and risk of toxicity.
Weight-based: 1-2 mg/kg lidocaine (max 4.5 mg/kg with epinephrine) per infiltration; do not exceed 4.5 mg/kg total dose.
Children: 1.1-1.8 mg/kg mepivacaine (0.54-0.9 mg/lb) as 2% solution with 1:20,000 levonordefrin; maximum 4.4 mg/kg (not exceeding 300 mg). For example, 20 kg child: 22-36 mg mepivacaine (1.1-1.8 m L of 2% solution).
Reduce dose by 50% due to decreased hepatic clearance and increased sensitivity; monitor for CNS and cardiovascular effects.
Elderly patients (≥65 years): use lowest effective dose due to increased sensitivity, potential renal impairment, and comorbidities. Maximum single dose: 4.4 mg/kg (not exceeding 300 mg); reduce dose by 50% if GFR < 50 m L/min. Monitor cardiovascular status due to levonordefrin.
Methemoglobinemia: Cases of methemoglobinemia have been reported, especially in infants and children. Use with caution in patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, or concurrent use with oxidizing agents.
Not available.
Risk of methemoglobinemia, especially in children <6 months; avoid use in patients with severe hepatic impairment; use caution with concurrent use of Class III antiarrhythmics; monitor for signs of systemic toxicity.
Risk of central nervous system toxicity (seizures, CNS depression),Cardiovascular toxicity (arrhythmias, hypotension) with high doses or rapid absorption,Avoid in patients with severe liver disease,May cause methemoglobinemia, especially in patients with glucose-6-phosphate dehydrogenase deficiency
Hypersensitivity to amide-type local anesthetics; severe hepatic impairment; known history of methemoglobinemia; use in children under 3 years of age for certain formulations.
Hypersensitivity to mepivacaine or other amide-type local anesthetics,Severe hypotension or cardiogenic shock,Porphyria,Administration via intravenous regional anesthesia (Bier block)
Avoid alcohol consumption for at least 24 hours after treatment as it may enhance CNS depression and reduce effectiveness. No specific food interactions; maintain normal diet but avoid hot/crunchy foods until anesthesia resolves.
Avoid high-tyramine foods (aged cheese, cured meats, fermented products) as concurrent MAO-A inhibition from levonordefrin may cause hypertensive crisis. Limit caffeine intake (stimulant additive effect on heart rate).
Lignospan Forte (lidocaine 2% with epinephrine 1:100,000) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects at doses up to 6 times the human dose. However, no adequate and well-controlled studies exist in pregnant women. Lidocaine crosses the placenta. In the first trimester, risk is minimal but should be used only if clearly needed. In second and third trimesters, no known fetal harm at standard doses, but epinephrine may reduce uterine blood flow; use lowest effective dose and avoid intra-arterial injection. Avoid in preeclampsia or uteroplacental insufficiency. There is a theoretical risk of fetal bradycardia with high plasma levels.
Mepivacaine hydrochloride with levonordefrin is classified as FDA Pregnancy Category C. In animal studies, mepivacaine has been associated with adverse fetal effects at high doses, but no well-controlled human studies exist. Levonordefrin is a vasoconstrictor; systemic absorption may reduce uterine blood flow, potentially causing fetal hypoxia. Risk in the first trimester is unknown; second and third trimester use may be associated with fetal bradycardia and acidosis if high doses are administered or inadvertent intravascular injection occurs. Use only if clearly needed.
Small amounts of lidocaine are excreted into breast milk. The milk-to-plasma (M/P) ratio is approximately 0.3-1.0. The relative infant dose is estimated at <5% of maternal weight-adjusted dose, considered safe during breastfeeding. Epinephrine is not significantly excreted due to rapid metabolism. Use of Lignospan Forte is compatible with breastfeeding; however, monitor for infant sedation or irritability with prolonged use.
Mepivacaine is excreted into breast milk in small amounts; the milk-to-plasma ratio is approximately 0.4-0.6. Levonordefrin is not expected to enter breast milk significantly. The American Academy of Pediatrics considers mepivacaine compatible with breastfeeding. However, observe the infant for signs of local anesthetic toxicity (e.g., drowsiness, irritability).
Pregnancy does not require dose adjustment for lidocaine; however, due to increased cardiac output and plasma volume in pregnancy, peak plasma levels of lidocaine may be lower. Epinephrine dose should be minimized as it may reduce placental perfusion. Use the smallest effective volume. In preeclampsia or hypertensive disorders, avoid or use with caution due to epinephrine's vasoconstrictive effects. No pharmacokinetic changes necessitate routine dose increase.
No specific dose adjustment is recommended for mepivacaine in pregnancy; however, plasma levels of mepivacaine may be lower due to increased volume of distribution and clearance. Use the lowest effective dose and avoid high doses or frequent administration to minimize fetal exposure. Levonordefrin dose should be limited to minimize vasoconstriction effects.
Lignospan Forte contains lidocaine 2% with epinephrine 1:100,000. Use in dental procedures for profound anesthesia and hemostasis. Avoid in patients with severe hypertension, hyperthyroidism, or on non-selective beta-blockers due to epinephrine. Maximum dose: 7 mg/kg lidocaine with epinephrine. Aspirate before injection to prevent intravascular administration. Onset: 2-5 min; duration: 60-90 min for soft tissue, 2-4 hours for pulpal anesthesia.
For dental procedures, limit dose to 1 cartridge (1.8 m L) per appointment due to levonordefrin's α-adrenergic effects. Avoid in patients with sulfite allergy (bisulfite preservative). Use with caution in severe cardiovascular disease, pheochromocytoma, or hyperthyroidism due to levonordefrin. Onset 2-3 min, duration 60-90 min (infiltration).
Avoid chewing on the anesthetized area until sensation returns to prevent accidental injury.,Numbness and tingling of lips, tongue, and face are normal; report any persistent numbness or pain beyond 24 hours.,Do not eat hot foods or liquids until anesthesia wears off to avoid burns.,Side effects may include dizziness, headache, or palpitations; seek medical attention if severe or prolonged.,Inform your dentist if you are pregnant, breastfeeding, or have heart disease, high blood pressure, or thyroid disorders.
Report any history of heart disease, high blood pressure, or sulfite allergy before injection.,You may feel temporary increased heart rate or palpitations due to the vasoconstrictor.,Numbness may last several hours; avoid chewing gum or eating until sensation returns.,Seek immediate medical attention if you experience chest pain, severe headache, or difficulty breathing.,Use only as directed by your dentist; do not exceed prescribed dose.
No interactions on record
"Concomitant use of prochlorperazine and mepivacaine may lead to additive central nervous system (CNS) depression, resulting in excessive sedation, respiratory depression, and increased risk of hypotension. Mepivacaine, a local anesthetic, can cause CNS excitation followed by depression, while prochlorperazine, a phenothiazine antipsychotic, directly depresses CNS function. This combination may also potentiate cardiotoxicity, including QT prolongation and arrhythmias, due to additive effects on cardiac conduction."
"Mepivacaine, an amide local anesthetic, and Dezocine, a mixed opioid agonist-antagonist, both exhibit dose-dependent central nervous system (CNS) depressant and respiratory depressant effects. When co-administered, additive or supra-additive CNS and respiratory depression can occur, leading to increased risk of sedation, confusion, respiratory depression, and potentially coma or apnea, particularly in patients with compromised respiratory function or those receiving high doses of either agent."
"The combination of gamma-hydroxybutyric acid (GHB) and mepivacaine can lead to additive central nervous system (CNS) depression and respiratory depression. Both drugs act as CNS depressants, with GHB enhancing GABAergic activity and mepivacaine blocking sodium channels, which may result in severe sedation, respiratory arrest, and hypotension. Concomitant use requires careful risk-benefit assessment and close monitoring."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LIGNOSPAN FORTE vs MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN, answered by our medical review team.
LIGNOSPAN FORTE is a Local Anesthetic with Vasoconstrictor that works by Lidocaine and prilocaine stabilize neuronal membranes by inhibiting sodium ion influx, thereby blocking initiation and conduction of nerve impulses.. MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN is a Local Anesthetic with Vasoconstrictor that works by Local anesthetic that blocks voltage-gated sodium channels in neuronal membranes, preventing propagation of action potentials and transmission of pain signals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LIGNOSPAN FORTE and MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN depend on the specific clinical indication. These are both Local Anesthetic with Vasoconstrictor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LIGNOSPAN FORTE is: Adults: 2% lidocaine with 1:100,000 epinephrine, max 7 mg/kg lidocaine (500 mg) without epinephrine or 4.5 mg/kg (300 mg) with epinephrine; for dental infiltration or nerve block, 1-2 m L per site.. The standard adult dose of MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN is: Dental infiltration or nerve block: 1-2 cartridges (36-72 mg mepivacaine; 0.009-0.018 mg levonordefrin) of 2% solution with 1:20,000 levonordefrin; maximum dose: 4.4 mg/kg mepivacaine (not to exceed 300 mg) per appointment.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LIGNOSPAN FORTE and MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LIGNOSPAN FORTE is classified as Category C. Lignospan Forte (lidocaine 2% with epinephrine 1:100,000) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects at doses up to 6 times. MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN is classified as Category C. Mepivacaine hydrochloride with levonordefrin is classified as FDA Pregnancy Category C. In animal studies, mepivacaine has been associated with adverse fetal effects at high doses,. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.